Based in the Angolan capital of Luanda, on Africa’s southwest coast, FoodCare is a dried food manufacturer that processes and ...

The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and ...

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Cassava-based foods are staples enjoyed by millions of people around the world. From Brazil, Venezuela, Colombia, Ecuador, to ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus to potential seizure treatments.

Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...

Cassava Technologies is set to roll out Nvidia’s artificial intelligence software at its South African data centers by June, ...

Headquartered in the UK, Cassava has a presence across Africa, the Middle East, Latin America and the United States. Through ...

Shares of Cassava Sciences (NASDAQ: NASDAQ: SAVA) plummeted 20% as the company announced the discontinuation of its Alzheimer’s disease development program for simufilam. The decision follows the drug ...

Cassava Sciences explores simufilam's potential for seizures in tuberous sclerosis. Results for Alzheimer's trials expected ...

A research team investigates how genome editing can be harnessed to accelerate cassava breeding and improve key traits.

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by doctors and short-sellers who expressed doubts about its experimental ...